Hepatic cancer drugs. Dan G. Duda - DF/HCC
However, the increasing numbers of chronic HCC carriers in the U. During this exciting time in the field of HCC basic science and clinical management, many changes are simultaneously occurring at multiple levels of our understanding and management of the disease.
Suddenly, there are several new choices of therapy to offer patients. Hepatocellular Carcinoma, 3rd edition addresses this fast-changing disease and gives the reader a clearer understanding of the many mechanisms involved in carcinogenesis of the liver. This comprehensive and detailed review of how to diagnose and treat hepatocellular carcinoma is written by international leaders in hepatic cancer drugs field, covering both clinical treatment choices and the basic science underlying HCC development.
Updated and enhanced from the last edition inHepatocellular Carcinoma, 3rd edition features 12 new chapters including discussion of molecular markers, molecular hepatocarcinogenesis, microenvironment, heterogeneity, the new and exciting contributions of immunotherapy, and updates on the major effective hepatitis therapies that will transform HCC incidence and perhaps also the therapy. This cutting-edge text hepatic cancer drugs a vital resource hepatic cancer drugs must-have for today's hepatic cancer drugs and medical and surgical oncologists.